Gap Analysis and Authoring

Accelerate your European MAA approvals with Freyr's gap analysis and authoring expertise. We offer strategic guidance, comprehensive document reviews, and expert CTD authoring to ensure Regulatory compliance and minimize submission risks.

Gap Analysis and Authoring - Overview

Whether an application is required for a new generic product application, or post-approval life-cycle maintenance, conducting thorough MAA submissions gap analysis and accurate authoring can be crucial when preparing any application. They help to minimize avoidable delays, and reduce the risks of rejection, and are thus important in leading to health authority approvals. A gap analysis review of submission documentation against the relevant European guidelines and Regulatory standards plays a significant role in identifying potential deficiencies in documentation submission and can also be important in determining issues for discussion at pre-submission meetings. Such reviews also help identify any risk areas and facilitate the preparation of a risk mitigation plan.

Following the completion of an MAA submission gap analysis exercise, the results must be reviewed in detail and a plan developed to address any issues identified. The plan may include generic medicine authoring to create new documents or amendment of existing documents to address issues with existing ones.

Freyr is an expert in Regulatory submissions, and, with a highly skilled cross-functional team, it assists applicants in determining the applicable HA requirements and can perform comprehensive, sequential gap analysis and document authoring for all phases of the Regulatory process.

Gap Analysis and Authoring - Expertise

  • Regulatory assessment and gap analysis of source documents/data for suitability in line with European health authority requirements
  • Identification of gaps and necessary mitigation strategies
  • Knowledgeable resources with previous experience in R&D, Quality and Analytical departments to help with in-depth reviews
  • Review of documents, data and reports to assess compliance with HA expectations
  • Implementation of best practices based on previous experience of MAA submissions gap analysis and authoring
  • Experienced resources with the skills to interpret European health authority guidance and requirements
  • Authoring CTD sections using CTD templates aligned with European health authority requirements for content and format
  • Authoring of other documentation in line with relevant guidelines to support post-approval submissions
Gap Analysis and Authoring

Celebrating Customers Success

 

Medicinal Products

Regulatory Affairs

India

Thank you for the timely support over the weekend, which allowed us to resubmit quickly after being notified. This continuously demonstrates Freyr's commitment towards our company’s milestones.

Director - Global Regulatory Affairs – Operations

India-based, Global Top Generic Pharma Company

 

Medicinal Products

Publishing

UK

I am sure you have heard by now that we have received our first-ever approval from the FDA for our Brands division. This is a major milestone for us as well as for my team here in Reg Ops. I would be remiss if I didn’t point out that we would not have been able to do this without the help of your dedicated team. From the original filing, then the following year of responses, all helped get us to final approval.

Thank you Freyr team for a job well done!

Sr. Director, Head of Regulatory Operations

Ireland-based, Global Specialty Pharmaceutical Company

 

Medicinal Products

Regulatory Affairs

USA

Please relate to the team the excellent job they have done on the IND reactivation. Specifically, the high-quality module 3, written by Freyr. It was very comprehensive, very few revisions were required, and we had no questions from Health Canada or FDA. No CMC questions: that was a first for me. So very responsive to my many requests, which I am sure can be frustrating but always helpful while producing excellent work.

Thank you for always being available and responding quickly and comprehensively to all my requests.

What a great team you have, Freyr.

Lynne McGrath

Regulatory Consultant

 

Medicinal Products

Regulatory Affairs

USA

Congratulations!!! ​

Thanks for your great support for a successful ANDA filing, especially to the publishing team. Heartfully appreciate their last hours of hard work.

Assistant Manager​

US-based, Leading, Complex Generic Pharmaceutical Products Company​

 

Medicinal Products

Regulatory Affairs

USA

Thank you all for the great support!​

CEO

US-based, Leading Innovative Pharmaceuticals Company​

 

Medicinal Products

Regulatory Affairs

USA

The ANDA receipt has been received! Thank you very much for your hard work, patience, and support for our work over the last couple of months. We are delighted that we were able to meet the timeline and hit an important corporate goal of our young company. ​

Thank you again, and we look forward to working with your team on the next project!

Senior Director of Business and Product Development​

US-based, Leading Innovator Pharmaceuticals Company​